AX 205
Alternative Names: AX205Latest Information Update: 19 Mar 2009
At a glance
- Originator SYGNIS Bioscience GmbH
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis
Most Recent Events
- 13 Dec 2006 AX 205 is still in active development
- 07 May 2003 Preclinical trials in Amyotrophic lateral sclerosis in Germany (unspecified route)